Asia Pacific Pregnancy Ovulation Testing Market Share

The Asia Pacific Pregnancy and Ovulation Testing market size is anticipated to reach USD 351 Billion by 2032 at CAGR 4.1% during the forecast period 2023-2032.

Pregnancy tests are kits capable of detecting hormones such as human chorionic gonadotropin (hCG) in urine. Ovulation tests, on the other hand, are capable of detecting an uptick in luteinizing hormone (LH) to decide the optimal time for conceiving children. Availability of ovulation monitors on e-commerce websites, awareness of fertility tests, and awareness of these tests made possible by various promotional marketing activities by major brands are likely to lead to an uptick in market demand over the forecast period.

Digitization of results to provide privacy to consumers has been made possible owing to pervasiveness of smartphones. For instance, the FIRST RESPONSE Pregnancy PRO Digital Test & App Access by Church & Dwight Co., sends accurate results to the consumer’s smartphone. But high costs of ovulation tests can act as a market deterrent.

Report Overview

This report allows the user to gain a deeper understanding of the ongoing events and trends in the Asia Pacific (APAC) market for pregnancy and ovulation testing. By correlating the historical data with key market dynamics, our analysts can make highly accurate projections in the report. MRFR’s report includes a thorough segmental analysis of the APAC market segmented by type, mode of purchase, end-user, and region with astute insights. This report has been prepared to assist industry participants in making informed decisions on growth strategies and operation management. Users will come across drivers, trends, opportunities, and restraints which are likely to influence the growth of the market during the assessment period.

Segment Overview

By type, the Asia Pacific pregnancy & ovulation testing market has been segmented into pregnancy and ovulation testing. The pregnancy testing segment is sub-segmented into blood-based and urine-based testing. This segment is touted to garner above average demand owing to advances in pregnancy testing kits and alarming cases of polycystic ovary syndrome (PCOS). Similarly, the ovulation testing segment is sub-segmented into fertility monitors and ovulation prediction kits.

By mode of purchase, the Asia Pacific pregnancy & ovulation testing market is segmented into prescription and non-prescription testing/over-the-counter (OTC) testing.  The non-prescription testing mode of purchase is projected to experience remarkable growth thanks to preference for home pregnancy tests and privacy concerns among women.

By end-user, the Asia Pacific pregnancy & ovulation testing market is segmented into fertility centers, hospitals and clinics, and others. The hospitals and clinics segment is likely to register a 5.8% CAGR during the forecast period owing to their propensity to handle large patient volumes.

The segments and sub-segments covered in the report are analyzed under six major regions – India, China, Japan, Republic of Korea, Australia, and Rest of Asia Pacific, with respective country-level market sizing. For the scope of research, the standard definition of the product/service “pregnancy and ovulation testing” is included in the report. The report discusses and interprets the current and future opportunities of the industry by delivering an unbiased growth assessment.

Players Covered

Gregory Pharmaceutical Holdings, Inc., Proctor & Gamble, TaiDoc Technology & Corporation, Mankind Pharma Ltd., Geratherm Medical AG, Fairhaven Health, LLC, Quidel Corporation, Piramal Enterprises Ltd., Cadila Healthcare Limited, and Church & Dwight Co., Inc., are noteworthy players in the Asia Pacific pregnancy and ovulation testing market.

The report offers comprehensive profiles on these market players and assesses their current standing in the Asia Pacific pregnancy and ovulation testing market. Company history coupled with annual turnover, segmental share, SWOT analysis, growth strategies, new product launches, mergers and acquisitions (M&A) activities, and latest R&D initiatives are outlined in the report.

Research Methodology

Market Research Future (MRFR) uses a combination of primary and secondary research to compile market reports. Primary data is accumulated from interviewing industry stalwarts and secondary research is collated by studying white papers and annual reports of leading players. Our analysts use top-down and bottom-up approaches to validate the findings of the report. The report comprises news, current trends, and future prospects related to the market, all of which can provide a thorough understanding of the market to clients. Industry leaders can make accurate business decisions based on our insights.

Analysis Period

• Base Year - 2020


• Projection Period - From 2018 to 2032


• Market Denomination - USD Billion


• Conversion Rate - Considered as per the respective financial years

Intended Audience

• Government Research Institutes


• Research and Development (R&D) Companies


• Diagnostic Laboratories


• Academic Institutes and Universities

For the scope of research, the report offers a comprehensive analysis of the Asia Pacific pregnancy and ovulation testing market.

Type

• Pregnancy Testing (hCG Detection)
  
  
  
  • Urine-based Testing
  
  
  • Blood-based Testing
  
  
  
  


• Ovulation Testing
  
  
  
  • Ovulation Prediction Kits
  
  
  • Fertility Monitors
  
  
  
  

Mode of Purchase

• Prescription Testing


• Non-prescription or OTC Testing

End-user

• Fertility Centers


• Hospitals & Clinics


• Others

Region

• Australia


• Republic of Korea


• India


• China


• Japan


• Rest of Asia Pacific